Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2013, Article ID 275945, 7 pages
Review Article

Serum Testosterone Level, Testosterone Replacement Treatment, and Prostate Cancer

1Gazi University School of Medicine, Department of Urology, Besevler, 06125 Ankara, Turkey
2Ministry of Health, Ankara Numune Research and Training Hospital Third Department of Urology, Sihhiye, 06120 Ankara, Turkey
3Sisli Memorial Hospital, Department of Urology, 34120 Istanbul, Turkey

Received 19 June 2013; Accepted 20 August 2013

Academic Editor: Axel S. Merseburger

Copyright © 2013 Ali Atan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


There has been an increase in the number of individuals seeking testosterone (T) replacement treatment (TRT) due to a decrease in their blood T levels. Prostate cancer (PCa) is also an important issue in the same age group. However, we, urologists, are anxious about PCa development after T treatment. This is because it has been assumed that T may cause PCa or exacerbate insidious PCa which is already present. In this paper, recent developments regarding the relationship between serum levels of sex hormone and prostate tissue, the causal relationship between T and development of PCa, the effect of TRT on the group of patients who are at high risk of developing PCa, the suitability of TRT for patients who have already been diagnosed with PCa, and the effect of TRT on serum prostate-specific antigen level are analyzed.